Category: drug costs

Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs

Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.

For The Asking, A Check Is In The Mail To Help Pay For Costly Drugs

It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.

No Cash, No Heart. Transplant Centers Require Proof Of Payment.

The case of a Michigan woman told to fundraise $10,000 for a heart transplant sparked viral outrage, but experts say “wallet biopsies” are common.

Podcast: KHN’s ‘What The Health?’ Reading The Tea Leaves In Blue Wave’s Wake

In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”

Democrats Taking Key Leadership Jobs Have Pocketed Millions From Pharma

Top House Republican also received more than $1 million from drugmakers since 2007.

Must-Reads Of The Week From Brianna Labuskes

Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.

Podcast: KHN’s ‘What The Health?’ Doctors, Guns And Lame Ducks

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss how the Democrats’ takeover of the House and other results from the Nov. 6 elections might affect health care, and what Congress may have in store for the lame-duck session.

House Dems In New Seats Of Power Will Steer Health Policy, Attack Drug Prices

Democrats, who have a history of championing the Affordable Care Act and railing about drug prices, will now chair several house committees.

Podcast: KHN’s ‘What The Health?’ Open Enrollment And A Midterm Preview

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Joanne Kenen of Politico discuss the start of open enrollment for individual health insurance plans for 2019 and preview what next week’s midterm elections might mean for health policy. Plus, Barbara Feder Ostrov of KHN and California Healthline talks to Julie about the latest NPR-KHN “Bill of the Month” feature.

Trump Adds A Global Pricing Plan To Wide Attack On Drug Prices, But Doubts Persist

Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.